Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3995344 | The Lancet Oncology | 2010 | 11 Pages |
Abstract
SummaryThe metabolic syndrome, as a cluster of cardiovascular risk factors, may represent an important connection between cancer treatment and its common late effect of cardiovascular disease. Insight into the aetiology of the metabolic syndrome after cancer treatment might help to identify and treat cancer survivors with increased cardiovascular risk. In this review, we summarise current knowledge on the prevalence and pathophysiology of the metabolic syndrome in cancer survivors, and discuss current intervention strategies with an emphasis on new developments.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Esther C de Haas, Sjoukje F Oosting, Joop D Lefrandt, Bruce HR Wolffenbuttel, Dirk Th Sleijfer, Jourik A Gietema,